Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus

On Thursday, September 10th, 2026, Immuneering Corporation (IMRX) took advantage of the 12th Annual Cantor Fitzgerald Global Healthcare Conference to promote its lead cancer drug, atebimetinib. The company highlighted promising early data on pancreatic cancer and a comprehensive plan to protect patients, but the path to a Phase III readout remains lengthy.

IMRX claims atebimetinib simultaneously targets tumors and safeguards patients, distinguishing it from most oncology programs. Phase II pancreatic cancer data demonstrated a median overall survival of 17.3 months, compared to 8.5 months in the historical MPACT benchmark. The drug showed good tolerability, with 84% of patients maintaining or gaining weight at three months and only a small percentage experiencing Grade 3 or higher side effects.

Phase III trials with more than 40 sites are ongoing, but top-line results are not anticipated until 2028. The company's Chief Executive Ben emphasized that Immuneering's mission is to create cancer drugs that both attack the tumor and help patients remain stronger during treatment. Most oncology research concentrates on tumor eradication alone, while Immuneering aims for a dual approach of tumor control and reduced side effects.

The lead program, atebimetinib, is a Deep Cyclic Inhibition MEK inhibitor targeting the MAPK pathway, a common disruption in cancer. This novel approach aims to block the pathway for several hours daily and then release it, depriving cancer cells of continuous signaling while enabling healthy cells to recover. The drug was granted a U.S. patent in summer 2024.

Despite promising clinical data, Immuneering has a market capitalization of $298 million, and the stock has declined by 43% over the past year. The company's balance sheet is strong, with more cash than debt, but it is rapidly depleting its cash reserves, a common situation for clinical-stage biotech companies. The discussion centered on Immuneering's Phase II first-line pancreatic cancer study.

In the trial, 55 patients receiving atebimetinib plus gemcitabine had a median overall survival of 17.3 months, compared to 8.5 months in the MPACT study, which represents a 104% improvement over the benchmark. The favorable tolerability profile included 84% of patients maintaining or gaining weight at three months, and only two categories of Grade 3 or higher treatment-related adverse events in more than 10% of patients.